Cell cycle progression: New therapeutic target for vascular proliferative disease

Circulation

Volumn 98, Issue 1, 1998, Pages 82-89

  Braun Dullaeus, Ruediger C ^a   Mann, Michael J ^a   Dzau, Victor J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Bypass; Genes; Molecular biology; Restenosis

Indexed keywords

AMINOPHYLLINE; AMRINONE; ANGIOPEPTIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; CELL CYCLE PROTEIN; COLCHICINE; CYCLINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; HEPARIN; NITRIC OXIDE DONOR; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SOMATOMEDIN C; TERBINAFINE; TRANSFORMING GROWTH FACTOR BETA; TRAPIDIL;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG TARGETING; GENE TARGETING; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VEIN BYPASS;

EID: 0032493266     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.1.82     Document Type: Review

References (115)

1. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (Parts I and II). Drugs. 1993;46:18-52, 249-262.
2. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791-804.
3. Walker LN, Bowen-Pope DF, Ross R, Reidy MA. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc Natl Acad Sci U S A. 1986;83:7311-7315.
4. Warner SJC, Libby P. Human vascular smooth muscle cells: target for and source of tumor necrosis factor. J Immunol. 1989;142:100-109.
5. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456-461.
6. Gospodarowics D, Ferrara N, Haaparanta T, Neufeld G. Basic fibroblast growth factor: expression in cultured bovine vascular smooth muscle cells. Eur J Cell Biol. 1988;46:144-151.
7. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
8. Clowes AW, Schwanz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56:139-145.
9. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
10. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
11. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin, and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;16:77B-88B.
12. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation. 1992;86(suppl III):III43-III-46.
13. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
14. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
15. Majeski MW, Lindner V, Twardzik DR, Reidy MA. Production of transforming growth factor beta-1 during repair of arterial injury. J Clin Invest. 1991;88:904-910.
16. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC. Nabel GJ. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest. 1993;91:1822-1829.
17. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? Circulation. 1994;89:1511-1517.
18. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991;18(suppl II):II-100-II-105.
19. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gordon D, Derynck R, Nabel GJ. Direct gene transfer of transforming growth factor beta-1 into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
20. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest. 1994;93:339-346.
21. Cox JL, Chaisson DA, Gotleib AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis. Prog Cardiovasc Dis. 1991;34:45-68.
22. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 1987;5:126-136.
23. Mann MJ, Gibbons GH, Kemoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A. 1995;92:4502-4506.
24. Katsuda S, Boyd HC, Fligner C, Ross R, Gown AM. Human atherosclerosis, III: immunocytochemical analysis of the cell composition of lesions of young adults. Am J Pathol. 1992;140:907-914.
25. Ingarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265-9269.
26. Kinsella MG, Wight TN. Modulation of sulfated proteoglycan synthesis by bovine aortic endothelial cells during migration. J Cell Biol. 1986; 102:678-687.
27. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996;274:1664-1671.
28. Pardee AB. G1 events and regulation of cell proliferation. Science. 1989;246:603-608.
29. Stillman B. Smart machines at the DNA replication fork. Cell. 1994;78:725-728.
30. Snerr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551-555.
31. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Gen Dev. 1995;9:1149-1163.
32. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
33. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and Gl/Sregulatory genes. Mol Cell Biol. 1995;15:4215-4224.
34. Hunter T. Oncoprotein networks. Cell. 1997;88:333-346.
35. Phuchareon J. Tokuhisa T. Deregulated c-Fos/AP-1 modulates expression of the cyclin and the cdk gene in splenic B cells stimulated with lipopolysaccharide. Cancer Lett. 1995;92:203-208.
36. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogenes and platelet-derived growth factor. Cell. 1983;35:603-610.
37. Shichiri M. Hanson KD. Sedivy JM. Effects of c-myc expression on proliferation, quiescence, and the GO to G1 transition in nontransformed cells. Cell Growth Differ. 1993;4:93-104.
38. Daksis JI, Lu RY, Facchini LM, Marhin WW. Penn LJ. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncagene. 1994;9:3635-3645.
39. Steiner P. Philipp A, Lukas J. Godden-Kent D. Pagano M, Mittnacht S. Bartek J. Eilers M. Identification of a myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 1995;14:4814-4826.
40. Hanson KD. Shichiri M, Follansbee MR, Sedivy JM. Effects of c-myc expression on cell cycle progression. Mol Cell Biol. 1994;14:5748-5755.
41. Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci. 1994;19:279-283.
42. Dobrowolski S, Harter M. Stacey DW. Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells. Mol Cell Biol. 1994;14:5441-5449.
43. Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ. Yang-Yen HF. Ras transformation results in an elevated level of cyclin Dl and acceleration of Gl progression in NIH 3T3 cells. Mol Cell Biol. 1995;15:3654-3663.
44. Leone G. DeGregori J, Sears R, Jakoi L, Nevins JR. Mac and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387:422-425.
45. Marhamati DJ. Sonenshein GE. B-Myb expression in vascular smooth muscle cells occurs in a cell cycle-dependent fashion and downregulates promoter activity of type I collagen genes. J Biol Chem. 1996;271:3359-3365.
46. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
47. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE. Kinzler KW. Vogelstein B. WAF1. a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
48. Waga S. Hannon GJ. Beach D. Stillman B. The p21 inhibitor of cyclindependent kinases controls DNA replication by interaction with PCNA. Nature. 1994;369:574-577.
49. Lowe SW. Schmitt EM, Smith SW, Osbome B. Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362: 847-849.
50. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Rasking WH. Reid BJ. A p53-dependent mouse spindle checkpoint. Science. 1995;267:1353-1356.
51. Del Sal GD, Ruaro EM, Utrera R, Cole CN, Levine AJ, Schneider C. Ras 1-induced growth suppression requires a transactivation-independent p53 function. Mol Cell Biol. 1995;15:7152-7160.
52. Gorski DH, Patel CV, Walsh K. Homeobox transcription factor regulation in the cardiovascular system. Trends Cardiovasc Med. 1993;3: 184-190.
53. Gorski DH, Le Page DF, Patcl CV, Copeland NG, Jenkins NA. Walsh K. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol. 1993;13:3722-3733.
54. King RW. Jackson PK, Kirschner MW. Mitosis in transition. Cell. 1994;79:563-571.
55. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science. 1996;274:1652-1658.
56. Pai SR, Bird RC. c-fos expression is required during all phases of the cell cycle during exponential cell proliferation. Anticancer Res. 1994;14:985-994.
57. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 1996;382:511-517.
58. Bom TL, Frost JA, Schonthal A, Prendergast GC, Feramisco JR. c-myc cooperates with activated ras to induce the cdc2-promoter. Mol Cell Biol. 1994;14:5710-5718.
59. Ku DH, Wen SC, Engelhard A. Nicolaides NC, Lipson KE. Marino TA, Calabretta B. c-myb transactivates cdc2 expression via Myb binding sites in the 5'-flanking region of the human cdc2 gene. J Biol Chem. 1993;268:2255-2259.
60. Travail S. Reiss K. Ferber A, Petralia S, Mercer WE, Calabretta B, Baserga R. Constitutively expressed c-myb abrogates the requirement for insulin-like growth factor 1 in 3T3 fibroblasts. Mol Cell Biol. 1991;11:731-736.
61. Miano JM, Vlasic N, Tola RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury: a putative in vivo mechanism for autocrine growth. Arterioscler Thromb. 1993;13:211-219.
62. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem. 1995;270:5457-5461.
63. Braun-Dullaeus RC, von der Leyen HE, Mann MJ. Zhang L. Morris RE, Dzau VJ. Loss of p27Kipl and Induction of Cdk1 in the rat carotid artery following balloon catheter injury: in vivo and in vitro influence of rapamycin. FASEB J. 1997;11:A153. Abstract.
64. Yang Z-Y, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury, Proc Natl Acad Sci U S A. 1996;93:7905-7910.
65. Aoyagi M. Yamamoto M, Azuma H, Nagashima G. Niimi Y, Hirakawa K. Yamamoto K. Expression of p53 protein and p53 gene transcripts in rabbit carotid arteries after balloon denudation. Histochem Cell Biol. 1997;107:365-370.
66. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimai hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
67. Morishita R, Gibbons GH, Ellison KE, Nakajima M. Zhang L, Kaneda Y. Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.
68. Abe J. Zhou W, Taguchi J, Takuwa N, Miki K, Okazaki H, Kurokawa K, Kumada M, Takuwa Y. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun. 1994;198:16-24.
69. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K. Andres V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty, Circ Res. 1997;80:418-426.
70. Pickering JG, Weir L, Jekanowsky J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest. 1993; 91:1469-1480.
71. O'Brien ER. Alpers CE, Stewart DK. Ferguson M, Tran N. Gordon D. Benditt EP, Hinohara T. Simpson JB, Schwartz SM. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 1993;73:223-231.
72. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation. 1996;93:848-852.
73. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs. Curr Opin Immunol. 1996;8:710-720.
74. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
75. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ. Abraham RT. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem. 1993;268: 22737-22745.
76. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKB inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
77. Cao W, Mohacsi P. Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995;59:390-395.
78. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation. 1993;55:1409-1418.
79. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMPinduced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclindependent kinase 4 activation. Cell. 1994;79:487-496.
80. L' Allemain G, Lavoie JN, Rivard N, Baldin V, Pouyssegur J. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene. 1997;14:1981-1990.
81. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G. Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 1997;3:775-779.
82. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol. 1997;272: H1810-H1818.
83. Tarry WC, Makhoul RG. L-Arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Artenoscler Thromb. 1994;14:938-943.
84. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271:20608-20616.
85. Cornwell TL. Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 1994;267:C1405-C1413.
86. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxidegenerating vasodilator in vascular smooth muscle cells. J Biol Chem. 1997;272:10050-10057.
87. Matsuo H, Furuya M. C-type natriuretic protein inhibits intimal thickening after vascular injury. Ann N Y Acad Sci. 1997;811:45-47.
88. Havlicek L, Hanus J, Vesely J, Leclerc S. Meijer L. Shaw G, Strand M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem. 1997;40:408-412.
89. Finkel T, Epstein SE. Gene therapy for vascular disease. FASEB J. 1995;9:843-851.
90. Laird JR, Carter AJ, Kufs WM, Hoopes TG, Farb A, Nott SH, Fischell RE. Fischell DR. Virmani R, Fischell TA. Inhibition of neointimal proliferation with low-dose irradiation from a beta-particle-emitting stent. Circulation. 1996;93:529-536.
91. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS. Russo RJ. Schatz RA, Guameri EM, Steuterman S, Morris NB, Leon MB. Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697-1703.
92. Simons M, Edelman ER. DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
93. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P. Dodge GR, Hall DJ, Shaheen F, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994;90:944-951.
94. Simons M, Edelman ER. Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest. 1994;93:2351-2356.
95. Morishita R, Gibbons GH, Kaneda Y, Ogihara T. Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 1994;149:13-19.
96. Dev V, Parikh A, Ren M, Goldenberg T. Fishbein MC, Eigler N, Rossi J, Litvack F. Ribozymes to cell division cycle (CDC-2) kinase and proliferating cell nuclear antigen (PCNA) prevent intimal hyperplasia in rat carotid artery. Circulation. 1995;92(suppl I):I-634. Abstract.
97. Morishita R, Gibbons GH, Horiuchi M. Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferalion in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
98. Mann MJ, Whittemore AD, Donaldson MC, Belkin MA, Orav EJ, Polak J, Dzau VJ, Preliminary clinical experience with genetic engineering of human vein grafts: evidence for target gene inhibition. Circulation. 1997;96(suppl I):I-4. Abstract.
99. Chang MW, Burr E. Seltzer J, Jiang YQ, Nabel GJ, Nabel EG. Parmacek MS. Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
100. Chang MW, Barr E, Lu MM. Barton K. Leiden JM. Adenovirusmediated over-expression of the cyclin/cyclin-dependent kinase inhibitor. p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
101. Yonemitsu Y, Kaneda Y, Hataa Y, Nakashima Y, Sueishi K. Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. Ann N Y Acad Sci. 1997;811:395-399.
102. Chen D, Krasinski K, Chen D, Sylvester A, Chen J, Nisen PD, Andres V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27KIP1, an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997;99:2334-2341.
103. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L. Nakajima M, Kaneda Y. Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
104. Maillard L, Belle EV, Perlman H, Branellec D. Barry J. Steg G, Walsh K. GAX adenovirus percutaneous gene transfer inhibits neointima formation in a rabbit model of balloon angioplasty. Circulation. 1996;94(suppl I):I-637. Abstract.
105. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G. Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, Chiariello M. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;1:541-545.
106. Mann MJ, Kernoff R, Dzau VJ. Intra-operative transfection with E2F decoy oligonucleotide yields long term resistance to vein graft atherosclerosis. J Invest Med. 1997;45:224A. Abstract.
107. Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE. Cooke JP, Buitrago R, Kemoff R, Dzau VJ. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest. 1997;99:1295-1301.
108. Biro S, Fu Y-M, Yu Z-X, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993;90: 654-658.
109. Fukui R, Shibata N, Kohbayashi E, Furutama D, Amakawa M, Negoro N, Nakakouji T, Li M, Ishihara T, Ohsawa N. Enhanced expression of the p21 cyclin-dependent kinase inhibitor(Cip1) after vascular injury and the inhibited migration of smooth muscle cells by Cip 1 : possible role for the neointimal formation. Circulation. 1996;94(suppl I):I-524. Abstract.
110. Poon M, Marx SO, Gallo R, Badimon JJ. Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
111. Hiraoka K, Sasaguri Y, Komiya S, Inoue A, Morimatsu M. Cell proliferation-related production of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin) by cultured human rheumatoid synovial fibroblasts. Biochem Int. 1992;27:1083-1091.
112. Schmidbauer G, Hancock WW, Wasowska B, Badger AM, KupiecWeglinski JW. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation. 1994;57: 933-941.
113. Pollman MJ, Hall JL, Mann MJ, Gibbons GH, Inhibition of neointimal cell Bcl-x expression induces apoptosis and regression of vascular disease. Circulation. 1997;96(suppl I):I-110. Abstract.
114. Li L, Miano JM, Mercer B, Olson EN. Expression of the SM22α promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol. 1996;132:849-859.
115. Clowes AW. Vascular gene transfer in smooth muscle cells. Ann N Y Acad Sci. 1997;811:293-297.